Q-omics provides the consensus-scored MAGEA9 profile across patient tissues and cancer cell-line models. MAGEA9 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, MAGEA9 is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, MAGEA9 protein abundance shows 9,634 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, LUSC, and GBM as cancer lineages where MAGEA9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAGEA9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAGEA9 survival associations across molecular data types. MAGEA9 RNA expression shows survival associations in the most cancer types (13), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAGEA9 RNA expression–survival associations across cancer types. High MAGEA9 expression shows unfavorable associations in BRCA, KICH, UCEC, ACC, TGCT and LUAD. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for MAGEA9 RNA expression.
This table summarizes MAGEA9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1, while mass-spec protein shows differences in 5. The strongest signals are observed in LUSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MAGEA9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAGEA9 shows higher tumor expression in LUSC. The LUSC box plot shows higher MAGEA9 RNA expression in tumor versus normal tissue (log2 FC = +0.567, t-test p < 0.001).
This table shows molecular features associated with MAGEA9 in patient tissues and cancer cell lines. In patient samples, MAGEA9 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MAGEA9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BREAST.
